Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

References

• Appelbaum F R, Gundacker H, Head D R, Slovak M L, Willman C L, Godwin J E, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing J R, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062
   PubMed Web of Science ®Google Scholar
• Chauncey T R. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 2001; 13: 21–26
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Chen IM, McConnell T, Slovak ML, Head DR, et al. Acute myeloid leukemia in the elderly: a biologically distinct disease in which MDR1 expression and unfavorable cytogenetics contribute to a poor clinical response. Studies of the Southwest Oncology Group. Acute leukemia VII-experimental approaches and novel therapies. Springer-Verlag, Heidelberg 1998; 413–421
   Google Scholar
• Willman C L. The prognostic significance of the expression and function of genes mediating multi-drug resistance in adult patients with acute myeloid leukemia: biologic and clinical studies of the Southwest oncology Group leukemia research program. Semin Hematol 1997; 34: 25–33
   PubMed Web of Science ®Google Scholar
• Goldstone A H, Burnett A K, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in elderly patients: the results of United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98: 1302–1311
   PubMed Web of Science ®Google Scholar
• Hiddeman W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, et al. Management of acute myeloid leukemia in the elderly patients. J Clin Oncol 1999; 17: 3569–3576
   PubMed Web of Science ®Google Scholar
• Godwin J E, Kopecky K J, Head DR, Willman CL, Leith CP, Hynes HE, et al. A double-blind placebo controlled trial of granulocyte colony stimulation factor in the elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998; 91: 3607–3615
   PubMed Web of Science ®Google Scholar
• Rowe J M, Neuberg D, Friedenberg W, Bennett JM, Paietla E, Makary AZ, et al. A Phase 3 study of three induction regimens and of priming with GM-CSF in older patients with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479–485
   PubMed Web of Science ®Google Scholar
• Sikic B I. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11: 1629–1635
   PubMed Web of Science ®Google Scholar
• Chauncey T R, Rankin A, Anderson JE, Chen I, Kopecky KJ, Godwin JC, et al. A Phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia using mitoxantrone, etoposide and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. Leuk Res 2000; 24: 567–574
   PubMed Web of Science ®Google Scholar
• Knipp H, Hildebrandt B, Giagounidis A, Kobbe G, Haas R, Aul C, et al. Intensive chemotherapy is not recommended for patients with acute myeloid leukemia or high-risk myelodysplastic syndromes aged over 60 years with complex karyotype abnormalities. Blood 2004; 104: 24a
   Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti G J, Santini V, Finelli C, Giagounidis A, Schoch R, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher risk MDS patients compared to conventional care regimens (CCR). Blood 2007; 110: 250a, abstract no. 817
   Web of Science ®Google Scholar
• Silverman L R, McKenzie D R, Peterson BL, Stone RM, Powell BR, Mayo C, et al. Response rates in patients with acute myeloid leukemia (AML) treated with azacytidine using WHO and International Working Group (IWG) criteria for myelodysplastic syndrome. Blood 2005; 106, abstract no. 1848
   PubMed Web of Science ®Google Scholar
• Larson R A, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627–1636
   PubMed Web of Science ®Google Scholar
• Linenberger M L, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, et al. Multidrug-resistance phenotype and clinical response to gemtuzumab ozogamicin. Blood 2001; 98: 988–994
   PubMed Web of Science ®Google Scholar
• Walter R B, Gooley T A, van der Velden V HJ, Loken M R, van Dongen J JM, Flowers D A, et al. CD33 expression and P-glycoprotein mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109: 4168–4170
   PubMed Web of Science ®Google Scholar
• van der Velden V HJ, te Marvelde J G, Hoogeveen PG, Bernstein ID, Houstmuller AB, Berger MS, et al. Targeting of the CD33-calicheamicin immunoconjugate mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197–3204
   PubMed Web of Science ®Google Scholar
• van der Velden V HJ, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M, et al. High CD33 antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia. Leukemia 2004; 18: 983–988
   PubMed Web of Science ®Google Scholar
• Yang As, Doshi K D, Choi SW, Mason JB, Mannari RK, et al. DNA methylation changes after decitabine therapy in patients with leukemia. Cancer Res 2006; 66: 5495–5503
   PubMed Web of Science ®Google Scholar